Company Profile

Lonza Group AG, together with its subsidiaries, operates as a contract development and manufacturing organization for pharma and biotech companies in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. It operates through Integrated Biologics; Advanced Synthesis; and Specialized Modalities segments. The Integrated Biologics segment offers CDMO biologics services from clinical development, drug substance, and drug product manufacturing; and operates mammalian and drug product platforms. Its Advanced Synthesis segment manufactures antibody-drug conjugates (ADCs) and other bioconjugates, small molecules, and highly potent active pharmaceutical ingredients; and operates small molecules and bioconjugates platforms. The Specialized Modalities segment operates various technologies, such as spanning cell & gene, microbial, bioscience, and mRNA. Lonza Group AG was incorporated in 1897 and is headquartered in Basel, Switzerland.

Latest News

VIC Properties and Vertical Aerospace Explore Electric Air Mobility as Pinheirinho Estate Looks Beyond Traditional Transportation Infrastructure

Business Wire • 07/27/2026

Home Control's Orbiva Signs Strategic MOU with Indonesia's Articura to Advance Localized Healthcare AI and AIoT Digital Health Ecosystem

PR Newswire • 07/27/2026

Royal Caribbean (RCL) Q2 Earnings Report Preview: What To Look For

StockStory • 07/27/2026

Did Molson Coors' (TAP) Steady Dividend Signal a Deeper Capital Allocation Shift Toward Premium Brands?

Simply Wall St. • 07/27/2026

Is ORIX (TSE:8591) Fully Valued Following Its New Debt Shelf Registration?

Simply Wall St. • 07/27/2026